<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00708292</url>
  </required_header>
  <id_info>
    <org_study_id>CAUY922A2103</org_study_id>
    <secondary_id>2007-006279-35</secondary_id>
    <nct_id>NCT00708292</nct_id>
  </id_info>
  <brief_title>A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.</brief_title>
  <official_title>An Open-label, Multi-center, Phase I-Ib/II Study of AUY922 Administered as Single Agent and in Combination With Bortezomib With or Without Dexamethasone in Adult Patients in Relapse or Refractory Multiple Myeloma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously
      in patients with multiple myeloma to determine the maximum tolerated dose. The Phase II part
      will investigate the efficacy of AUY922 in patients with multiple myeloma. Additionally, the
      study includes a Phase Ib combination part of AUY922 administered in combination with
      bortezomib, to determine the maximum tolerated dose of the combination drugs in patients with
      multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safe dose of AUY922 when administered once a week.</measure>
    <time_frame>54 weeks (Maximum Tolerated Dose (MTD))</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safe dose of AUY922 when administered once a week in combination with bortezomib and dexamethasone.</measure>
    <time_frame>24 weeks (MTD determination of dual and triple combination)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of AUY922 administered once a week alone and in combination</measure>
    <time_frame>at baseline and every 2 cycles (time to document tumor progression)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Single Agent AUY922</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AUY922 + Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AUY922 + Bortezomib + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUY922</intervention_name>
    <arm_group_label>Single Agent AUY922</arm_group_label>
    <arm_group_label>AUY922 + Bortezomib</arm_group_label>
    <arm_group_label>AUY922 + Bortezomib + Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <arm_group_label>AUY922 + Bortezomib</arm_group_label>
    <arm_group_label>AUY922 + Bortezomib + Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>AUY922 + Bortezomib + Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients must have a diagnosis of active multiple myeloma.

          -  Phase I and Phase II part: Patients must have received at least 2 but not more than 4
             prior line of therapy and their disease has progressed during or after last therapy.

          -  Phase Ib part: Patients must have received no more than 2 prior lines of therapy
             (excluding dexamethasone as single agent).

          -  ECOG Performance Status of ≤ 2.

          -  Patients must have acceptable neutrophil and platelet counts as well as adequate
             kidney and liver function.

          -  Patients must have magnesium levels above lower limit of normal or correctable with
             supplements.

          -  Patients must be willing and able to undergo bone marrow biopsy/aspirate.

          -  Able to sign informed consent.

        Exclusion criteria:

          -  Prior treatment with any HSP90 or HDAC inhibitor for the treatment of multiple
             myeloma.

          -  Patients with unresolved diarrhea ≥ CTCAE grade 2.

          -  Patients with acute or chronic liver disease.

          -  Patients using medications that have a relative risk of prolonging the QT interval.

          -  Clinically significant cardiac diseases.

          -  Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g.
             Gilbert's syndrome).

          -  Pregnant or lactating women.

          -  Fertile women of childbearing potential (WCBP) not using adequate contraception.

          -  Male patients whose partners are WCBP, not using adequate contraception.

          -  Patients who unwilling or unable to comply with the protocol.

          -  Phase Ib part: Peripheral neuropathy ≥ CTCAE grade 1.

          -  Phase Ib part: Prior treatment with bortezomib.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona Cancer Clinical Research Unit</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center / UT Health Science Center InstituteForDrugDevelopment(3)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2008</study_first_submitted>
  <study_first_submitted_qc>July 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2008</study_first_posted>
  <disposition_first_submitted>May 1, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 1, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 3, 2012</disposition_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AUY922</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>HSP90 inhibitors</keyword>
  <keyword>Phase I/II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

